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ABSTRACT In 2014, the method of data collection from NHS trusts in England for the National Lung
Cancer Audit (NLCA) was changed from a bespoke dataset called LUCADA (Lung Cancer Data). Under
the new contract, data are submitted via the Cancer Outcome and Service Dataset (COSD) system and
linked additional cancer registry datasets. In 2014, trusts were given opportunity to submit LUCADA data
as well as registry data. 132 NHS trusts submitted LUCADA data, and all 151 trusts submitted COSD data.
This transitional year therefore provided the opportunity to compare both datasets for data completeness
and reliability.
We linked the two datasets at the patient level to assess the completeness of key patient and treatment
variables. We also assessed the interdata agreement of these variables using Cohen’s kappa statistic, κ.
We identified 26001 patients in both datasets. Overall, the recording of sex, age, performance status and
stage had more than 90% agreement between datasets, but there were more patients with missing
performance status in the registry dataset. Although levels of agreement for surgery, chemotherapy and
external-beam radiotherapy were high between datasets, the new COSD system identified more instances
of active treatment.
There seems to be a high agreement of data between the datasets, and the findings suggest that the
registry dataset coupled with COSD provides a richer dataset than LUCADA. However, it lagged behind
LUCADA in performance status recording, which needs to improve over time.
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ORIGINAL ARTICLE
LUNG CANCER
Introduction
The National Lung Cancer Audit (NLCA) was established in 2004 to measure the process and outcomes
of care for people with lung cancer [1]. Until recently, each of the 151 National Health Service (NHS)
trusts in England uploaded the dataset, known as LUCADA (Lung Cancer Data), annually, using a
bespoke system, to a centralised infrastructure provided by the Health and Social Care Information Centre
(HSCIC), while separate arrangements were provided for other UK countries to submit data. Although
participation in the audit was not mandatory, studies have validated the LUCADA data and shown it to be
reliable and representative of lung cancer patients in England [1], and the ascertainment of cases and data
completeness improved considerably from 2008 onwards [2]. LUCADA data have been linked to other
databases, such as Hospital Episode Statistics (HES), to identify additional cases of surgery and
chemotherapy [3, 4], which were not recoded in LUCADA. In addition, HES data has been used to add a
comorbidity index (Charlson Score) based on previous inpatient admissions [4, 5].
In part due to the success of LUCADA, a national cancer dataset (Cancer Outcome and Service Dataset
(COSD)) with generic and site-specific data items has been developed over the past 10 years by the
National Cancer Intelligence Network (NCIN) and the English National Cancer Registration and Analysis
Service (NCRAS). Since January 2013, this dataset has become the national standard for reporting all
cancer activity in the NHS in England. In 2014, the contract for delivery of the National Lung Cancer
Audit was transferred to the Royal College of Physicians (RCP) and, as part of the new contractual
arrangements, a new methodology of data collection has been introduced that utilises the COSD, together
with other sources of cancer registration data including HES (referred to as the “registry dataset”).
During the transition phase to the new contract (covering patients diagnosed in 2014), it became apparent
that NHS trusts might not be as far advanced with monthly COSD submissions as had been hoped, and
the trusts were offered a one-off opportunity to submit a LUCADA data file. 132 NHS trusts took up this
offer. This dual data entry in 2014 presents a one-time opportunity to assess the data completeness of the
COSD (submitted monthly), validate key patient data fields, and assess the interdata agreement of
treatment data in comparison to the established and validated LUCADA dataset.
Methods
Comparison of the two datasets
LUCADA 2004–2014
LUCADA is a longitudinal validated database [1], which, in its final iteration, contained 103 key data
items on people with lung cancer. In this study, we have used the LUCADA data files submitted in June
2015 by 132 of the 151 English NHS trusts. These files include data on people diagnosed with lung cancer
in 2014.
COSD and registration data 2014 onwards
The COSD dataset contains data on core cancer and also lung-specific data items. NHS hospitals in
England submit a COSD file to the NCRAS each month for all new cancer cases. The data in the file
contribute to the registration process for each new cancer, together with data from pathology reports,
patient administration systems and treatment datasets. At the time of analysis of the 2014 data, the
detailed radiotherapy and chemotherapy treatment datasets were not available for linkage.
Data linkage and data management
We linked the people with lung cancer in the two datasets using anonymised NHS numbers, and
conducted a cross-sectional analysis on all patients in the LUCADA and registry datasets who were first
diagnosed in England between January 1, 2014 and December 31, 2014. We excluded people with
mesothelioma from this study.
Both LUCADA and the registry dataset include a number of similar data items, including age, sex, lung
cancer stage, performance status, pathological diagnosis and anticancer treatment (with dates), in addition
to lung cancer pathway data (e.g. whether a patient was assessed by a lung cancer nurse specialist and the
date the patient was discussed at a lung cancer multidisciplinary team (MDT)). Lung cancer morphology
was defined using the recorded Systematised Nomenclature of Medicine (SNOMED) codes where
available, and patients with unrecorded SNOMED code were “presumed” to have nonsmall cell lung
cancer (NSCLC). Performance status in both datasets is classified according to the World Health
Organization definition, and lung cancer stage is defined using the Union for International Cancer
Control definitions.
We considered a patient to have received active anticancer treatment (surgery, chemotherapy,
external-beam radiotherapy or brachytherapy) if they had a date of treatment in the LUCADA. In the
registry dataset, we identified Office of Population Census and Survey Classification of Intervention
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version 4 (OPCS-4) codes that correspond to curative surgical treatment with a valid date, which were
defined as 1 month before to 6 months after diagnosis date. Chemotherapy, external-beam radiotherapy
and brachytherapy records were also identified with the earliest date of treatment in the registry data
during the same period.
Statistical analysis
All analyses were performed using STATA 12. Initially, we assessed the proportion of patients who were
matched and present in both datasets. We then compared proportions of key patient variables, including
age, sex, performance status, lung cancer stage and anticancer treatment and the differences in key dates in
both datasets, including date of diagnosis and date discussed at a lung cancer MDT. We assessed the
interdata agreement between LUCADA and the registry dataset for these variables using Cohen’s kappa
statistic, κ. For ordered categorical variables such as performance status and stage, we used weighted kappa
to put more emphasis on variation across categories. Finally, we assessed the differences in patients who
were matched in the registry dataset and LUCADA and those patients who belonged to the 132
represented in the 2014 LUCADA audit but were not matched.
Results
The registry and LUCADA datasets used in our analyses consisted of 35518 patients from 151 trusts and
27995 patients from 132 trusts, respectively. 26001 patients were present in both datasets (figure 1). 1994
(7%) of the people recorded in LUCADA did not have an entry in the registry dataset, while 9517 (26.7%)
patients in the registry dataset did not have an entry in the LUCADA database. Of these 9517 patients,
3482 (37%) patients belonged to one of the 19 trusts who were not included in the 2014 LUCADA audit
report and were excluded from further analysis, while 6035 (63%) remained unmatched.
Patient variable agreement
Table 1 presents the difference in recording dates and agreement between the two datasets. Of the 26001
patients present in both datasets, 14680 (56%) had a different date of diagnosis in the LUCADA and
registry datasets, but this difference was often small, with 19218 (74%) diagnosis dates within 7 days and
22358 (86%) within 14 days of each other. For the date of discussion at an MDT in the two datasets, 7397
(28%) had different dates but 18293 (70%) were within 7 days and 19124 (74%) were within 14 days of
each other.
For key patient variables, the proportion distribution of sex and age were similar in the LUCADA and
registry datasets. 23 patients had different recorded sex and 838 patients had different age recorded (99%
of which were within 1 year of each other). There was a high level of agreement for sex and age
(agreement=99% and κ=0.99). The registry dataset had a larger proportion of patients with missing
performance status values compared with the LUCADA (27% versus 11%). Excluding missing values of
performance status, we assessed the agreement of performance status in the two databases, which was
found to be 97% (κ=0.91). We also looked at the agreement of stage recording in the two datasets,
excluding missing stage data, and this was 94% (κ=0.81).
Treatment data agreement
Table 2 presents the agreement of treatment data in the LUCADA and registry datasets. In general, we
identified more patients receiving surgery (4127 versus 3657), chemotherapy (8775 versus 7918),
radiotherapy (7739 versus 7417) and brachytherapy (34 versus 27) in the registry dataset compared with
n=9517  (26.7%)
not merged
Registry dataset n=35 518 LUCADA dataset n=27 995
n=1994  (7%) not merged
(excluded)
n=26 001 (73% of registry) or 
(93% of LUCADA) merged
FIGURE 1 Data merging of registry dataset and LUCADA (Lung Cancer Data).
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the LUCADA dataset. Out of the patients who had surgery or chemotherapy in both datasets, around 90%
of the patients had the same treatment date (2961 patients out of 3414 for surgery and 6865 patients out
of 7650 patients for chemotherapy), with an agreement of more than 90% (κ=0.85 and κ=0.88,
TABLE 1 Key patient features across the registry dataset and LUCADA (Lung Cancer Data) for
the 132 National Health Service trusts and level of agreement (n=26001)
Key variables Registry database LUCADA database Agreement κ
Sex
Female 11990 (46%) 11987 (46%)
Male 14011 (54%) 14014 (54%) 99% 0.99
Age years
<65 6032 (23%) 6025 (23%)
65–80 14249 (55%) 14242 (55%)
>80 5720 (22%) 5734 (22%) 99% 0.99
Pathology confirmed
No 6341 (24%) 7664 (29)
Yes 19660 (76%) 18337 (71%) 89% 0.73
Lung cancer type
Small cell 2975 (11%) 2958 (11%)
Carcinoid 189 (1%) 234 (1%)
Nonsmall cell 22837 (88%) 22809 (88%) 97% 0.87
Performance status
0 3816 (15%) 4278 (16%)
1 6550 (25%) 7869 (30%)
2 4025 (15%) 5109 (20%)
3 3553 (14%) 4527 (17%)
4 1152 (4%) 1424 (5%) 97% 0.91#,¶
Missing 6905 (27%) 2794 (11%) 83% 0.57#
Stage
IA 2976 (8%) 2226 (9%)
IB 2296 (6%) 1714 (7%)
IIA 1405 (4%) 1087 (4%)
IIB 1236 (4%) 1025 (4%)
IIIA 3981 (11%) 3330 (13%)
IIIB 2844 (8%) 2470 (9%)
IV 16758 (47%) 12258 (47%) 96% 0.90#,¶
Missing 4022 (11%) 1891 (7%) 94% 0.81#
#: weighted κ; ¶: excluding missing data.
TABLE 2 Treatment data agreement across registry dataset and LUCADA (Lung Cancer Data)
for matched patients (n=26001)
Registry dataset LUCADA Patients with the
same date in two
datasets
Patients with
±1 day in two
datasets
Agreement κ
No Yes
Surgery
No 21631 243
Yes 713 3414 2961 (87%) 3301 (97%) 96% 0.86
Chemotherapy
No 16958 268
Yes 1125 7650 6865 (90%) 6928 (91%) 95% 0.88
External-beam
radiotherapy
No 17214 1048
Yes 1370 6369 6002 (94%) 6073 (95%) 91% 0.77
Brachytherapy
No 25951 16
Yes 23 11 10 (91%) 10 (91%) 99% 0.36
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respectively) in the two datasets. 97% of the surgery dates and 91% of the chemotherapy dates were within
1 day of each other. We observed good agreement (κ=0.77) for the recording of radiotherapy, with 94% of
the patients having the same date of radiotherapy in the two datasets, but the lowest agreement was seen
with brachytherapy (κ=0.36).
Comparison for matched and unmatched patients within COSD
Table 3 shows results of the comparison of key patient variables for patients from the 132 trusts within the
registry dataset who were matched (n=26001) with patients in the LUCADA and who were not matched
(n=6032). There was no difference in the proportion distribution for sex between the two groups; however,
patients who were not matched had a higher proportion of older patients compared with the matched
group (29% versus 22%). We also found that the unmatched patients had a higher proportion of missing
performance status (69% versus 27%) and stage (31% versus 6%) compared with the other group. For
treatment received, the matched patients had a higher proportion of patients who received surgery (16%
TABLE 3 Patient feature comparison for matched and unmatched patients in the registry
dataset (n=32036)
LUCADA and registry merged
patients from 132 trusts
LUCADA and registry unmerged
patients from 132 trusts
Patients 26001 6035
Sex
Female 11990 (46%) 2867 (48%)
Male 14011 (54%) 3168 (52%)
Age years
<65 6032 (23%) 1287 (21)
65–80 14249 (55%) 3023 (50)
>80 5720 (22%) 1725 (29)
Performance status
0 3816 (15%) 394 (7%)
1 6550 (25%) 639 (11%)
2 4025 (15%) 342 (6%)
3 3553 (14%) 384 (6%)
4 1152 (4%) 131 (2%)
Missing 6905 (27%) 4145 (69%)
Stage
IA 2190 (8%) 502 (8%)
IB 1836 (7%) 271 (4%)
IIA 1096 (4%) 184 (3%)
IIB 1018 (4%) 131 (2%)
IIIA 3267 (13%) 385 (6%)
IIIB 2353 (9%) 230 (4%)
IV 12699 (49%) 2443 (41%)
Missing 1542 (6%) 1889 (31%)
Lung cancer type
Small cell 2975 (11%) 382 (6%)
Carcinoid 189 (1%) 98 (2%)
Nonsmall cell 22837 (88%) 5555 (92%)
Surgery
No 21825 (84%) 5252 (87%)
Yes 4176 (16%) 783 (13%)
Chemotherapy
No 17226 (66%) 5031 (83%)
Yes 8775 (34%) 1004 (17%)
External-beam
radiotherapy
No 18262 (70%) 5198 (86%)
Yes 7739 (30%) 837 (14%)
Brachytherapy
No 25967 (99.9%) 6026 (99.9%)
Yes 34 (0.1%) 9 (0.1%)
LUCADA: Lung Cancer Data.
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versus 13%), chemotherapy (34% versus 17%) and external-beam radiotherapy (30% versus 14%) compared
with the patients who were not matched.
Post hoc validation
As a result of our initial analyses, we conducted two post hoc investigation of patients who were present in
one database but not the other. For patients who were identified by the registry and not LUCADA
(n=6035), we investigated patients first diagnosed in 7 NHS trusts (n=583 (10%)) and summarised the
reason for their exclusion from the LUCADA dataset. We also investigated 70 random patients out of 1994
patients (3.5%) who were in LUCADA but not in the registry dataset by sending the anonymised patient
identification to Public Health England to assess their reason for exclusion from the registry dataset.
Our review of patients identified by the cancer registry but not LUCADA for 7 out of 132 NHS trusts
(n=583) revealed that 33% (n=193) had an error in data entry or submission to the system, 8% (n=45) did
not have a primary lung cancer diagnosis, 10% (n=57) had either a recurrent diagnosis of lung cancer, had
no documentation of cancer in the system, or were not from an English trust, 4% (n=22) had a diagnosis
year outside the analysis period, and 46% (n=266) had incorrect recording of the trust where the patient
was first seen by a physician. Our review of the sample of 70 patients in the LUCADA but not in the
registry dataset found that the majority of the patients had a diagnosis date outside the analysis period
(58%) while others were subsequently entered in the COSD system (after the raw data were provided to us
for the analysis as the data entry is an open process) (33%). This could be because the old
LUCADA-based audit relied on “date first seen by a lung cancer specialist”, whereas the new registry
system relies on the date of diagnosis of lung cancer, which can lead to patients first seen late in a year in
the LUCADA system being allocated in the registry data for the subsequent year.
Overall survival
We compared the median survival in days for patients who were present in both datasets (n=26001), those
belonging to the 19 trusts who only submitted LUCADA data (n=3482) and the extra patients identified
through the registry system (n=6035). Figure 2 presents a Kaplan–Meier curve showing that patients who
were present in both datasets had a better median day survival (234 days, interquartile range (IQR) of
64–608 days) compared with the 19 trusts who submitted LUCADA data (202 days) and the extra patients
(105 days). This difference was accounted for when we adjusted for patient features including age, sex,
performance status, stage and lung cancer type (figure 3).
Discussion
Our results demonstrate that that the new system for collecting lung cancer audit data using the cancer
registration process identifies a greater number of patients with lung cancer compared to the legacy
LUCADA submission process. For patients that were represented in both datasets, there was over 95%
agreement for key patient features including age, sex, lung cancer type and stage of disease. There was a
higher proportion of missing data on performance status (16% higher) in the registry dataset compared
with LUCADA. The new registry dataset identified more patients who received treatment with surgery,
chemotherapy and external-beam radiotherapy compared with LUCADA. We also observed that the
patients who were identified in the registration dataset but not LUCADA tended to be older, with higher
rates of missing performance status and stage information and a lower proportion of recorded active
FIGURE 2 Kaplan–Meier curve of
survival (in days) by data source.
LUCADA: Lung Cancer Data; COSD:
Cancer Outcome and Service
Dataset.
0
0.00
0.25
0.50
0.75
1.00
200
Analysis time days
Both datasets
Extra patients identified through COSD
Su
rv
iv
al
19 LUCADA only trust patients
400 600
https://doi.org/10.1183/23120541.00003-2017 6
LUNG CANCER | A. KHAKWANI ET AL.
treatment including surgery and chemotherapy. In summary, the new system seems to perform better than
its predecessor in all areas except completeness of performance status data.
The additional patients identified in the registry dataset but not LUCADA are probably a result of the
multiple sources of data that are used by cancer registration officers to register a case of lung cancer, with
increased opportunities for patients to be identified. In addition to the registry dataset, which largely
replicates LUCADA, the NCRAS also has direct access to pathology reports and death certificates, which
are less reliant on hospital informatics systems for submission. The fact that these extra patients tended to
be older, with less complete performance status data and less likely to receive active treatment, raises the
possibility that there is a cohort of lung cancer patients that hospital lung cancer MDTs are not aware of
and were not previously included in the audit. We also suspect that these patients missed out on being
discussed by the MDT because of their short survival.
The higher level of agreement for key data items in patients represented in both datasets is encouraging.
Although there were discrepancies between the two datasets for the dates of an event (e.g. date of
diagnosis and date of surgery), most of these dates lay very close to each other and so would not
significantly affect analysis of treatment times or survival. Similarly, although more patients were identified
as having received active treatment in the registration dataset, the treatment rates expressed as a proportion
of the whole population were similar to those reported via LUCADA in the 2013 report [6] (e.g. surgery:
15.5% registry versus 15.1% LUCADA). Accurate recording of performance status is important to allow
robust risk adjustment of patient outcomes, so it was disappointing to find that this field was incomplete
in 27% of patients in the registry dataset. However, it is anticipated that completeness for performance
status will improve as lung cancer teams become more familiar with the new process for data submission.
One of the limitations of the registry dataset, which also existed for the LUCADA dataset, is the lack of
detailed information collected on chemotherapy and radiotherapy, in particular the dose and number of
cycles or fractions of treatment [3, 7]. However, the Systemic Anticancer Therapy (SACT) and
Radiotherapy Datasets (RTDS) will become linked with the COSD system and form part of an even
complete registry dataset in due course.
Conclusion
In general, the registry dataset with the COSD system is a more effective dataset than the LUCADA
dataset, as it has better recording of pathology and treatment information, including surgery and
chemotherapy, while other patient features have a similar level of completeness. Although the missing
information of performance status is high in the 2014 registry data, it is anticipated that trusts will strive
to improve this in future years. The results from the lung cancer audit shows that this is an excellent
model to assess nationwide cancer practices and can lead to standardising cancer pathways and care for
other cancers.
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